Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
暂无分享,去创建一个
Nicolas Carlier | Aurélien Corneau | Nicolas Roche | Darragh Duffy | Nathalie Marin | Rémy Gauzit | Jean-Marc Treluyer | F. Rieux-Laucat | A. Fischer | N. Roche | S. Kernéis | D. Duffy | L. Mouthon | F. Pène | J. Hadjadj | V. Bondet | F. Rozenberg | C. Blanc | H. Péré | D. Veyer | B. Terrier | Alain Fischer | B. Charbit | P. Tharaux | R. Gauzit | J. Treluyer | Luc Mouthon | C. Chenevier-Gobeaux | S. Merkling | N. Yatim | Flore Rozenberg | Solen Kernéis | Pierre-Louis Tharaux | Benjamin Terrier | N. Smith | Nikaïa Smith | Nader Yatim | Frédéric Pène | Frédéric Rieux-Laucat | Hélène Péré | Jérôme Hadjadj | Laura Barnabei | Jeremy Boussier | Bruno Charbit | Vincent Bondet | Camille Chenevier-Gobeaux | Paul Breillat | Caroline Morbieu | Tali-Anne Szwebel | Sarah H. Merkling | David Veyer | Catherine Blanc | L. Barnabei | N. Marin | T. Szwebel | J. Boussier | P. Breillat | C. Morbieu | A. Corneau | N. Carlier | Nikaïa Smith
[1] Deborah R. Taylor,et al. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products , 2006, Transfusion.
[2] M Aguet,et al. Functional role of type I and type II interferons in antiviral defense. , 1994, Science.
[3] J. Baillie,et al. Host susceptibility to severe influenza A virus infection , 2019, Critical Care.
[4] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[5] Matthew Rowland,et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed , 2020, The Lancet.
[6] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[7] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[8] T. Uyeki,et al. Influenza virus-related critical illness: prevention, diagnosis, treatment , 2019, Critical Care.
[9] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[10] O. Ramilo,et al. Immune profiles provide insights into respiratory syncytial virus disease severity in young children , 2020, Science Translational Medicine.
[11] Jesús Hernández,et al. Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity , 2016, Inflammation.
[12] J. Aicardi,et al. Early intrathecal synthesis of interferon in herpes encephalitis. , 1979, Biomedicine / [publiee pour l'A.A.I.C.I.G.].
[13] B. Reizis. Plasmacytoid Dendritic Cells: Development, Regulation, and Function , 2019, Immunity.
[14] I. Amit,et al. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients , 2020, Cell.
[15] L. Prokunina-Olsson,et al. COVID-19 and emerging viral infections: The case for interferon lambda , 2020, The Journal of experimental medicine.
[16] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[17] D. Chaussabel,et al. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency , 2015, Science.
[18] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[19] R. Schwartz,et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.
[20] A. Vallée,et al. Interleukin-6 blockade for severe COVID-19 , 2020, medRxiv.
[21] J. Lessler,et al. Estimating the burden of SARS-CoV-2 in France , 2020, Science.
[22] T. Molina,et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. , 2014, The Journal of clinical investigation.
[23] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.
[24] J. Rehwinkel,et al. RIG-I-like receptors: their regulation and roles in RNA sensing , 2020, Nature Reviews Immunology.
[25] K. He,et al. Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection , 2020 .
[26] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[27] Friedrich Teuscher,et al. How robust are tests for two independent samples , 2007 .
[28] Sean C. Bendall,et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.
[29] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[30] K. Ley,et al. Immune and inflammatory mechanisms of atherosclerosis (*). , 2009, Annual review of immunology.
[31] G. Cheng,et al. Systematic identification of type I and type II interferon-induced antiviral factors , 2012, Proceedings of the National Academy of Sciences.
[32] Y. Ho,et al. SARS-CoV-2: A Storm is Raging. , 2020, The Journal of clinical investigation.
[33] F. Rieux-Laucat,et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.